Sign inJoin waitlistJoin the waitlist

Neil E. Kay

Consultant, Division of Hematology, Department of Internal Medicine · Mayo Clinic

Credentials: · · · ·

History

Mayo Clinic
Present

Research

National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment
Blood · 1996 · 1,521 citations
Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia
New England Journal of Medicine · 2014 · 1,369 citations
ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia
New England Journal of Medicine · 2004 · 706 citations

Tait Shanafelt
172 papers · 30 as a fellow
TC
Timothy Call
142 papers
Sameer Parikh
103 papers
JL
Jose Leis
73 papers
Curtis Hanson
68 papers
WD
Wei Ding
68 papers
Clive Zent
58 papers
MO
Martin Oken
31 papers
JB
John Byrd
29 papers
Paul Hampel
29 papers · 14 as a resident
EM
Eli Muchtar
28 papers
Amber Koehler
27 papers

Grants

Outcomes for CLL Patients Treated with Novel Therapy
National Cancer Institute · R01
Contact PI · $4M · Mayo Clinic Rochester
2021–2031
Rewiring Oncogenic Pathways to Induce Cell Death in Chronic Lymphocytic Leukemia
National Cancer Institute · R01
PI · $661.1K · Stanford University
2026–2029
Predicting Clinical Outcome in Individuals with Small CLL B Cell Clones
National Cancer Institute · R01
Contact PI · $3M · Mayo Clinic Rochester
2015–2021
Predicting Clinical Outcome After Traditional and Ibrutinib-Based Therapy In Chronic Lymphocytic Leukemia
National Cancer Institute · R01
Contact PI · $1.8M · Mayo Clinic Rochester
2015–2021

Clinical trials

Hematopoiesis in MBL and CLL Versus Healthy Age-Matched Control Subjects
Principal investigator · Recruiting
Mayo Clinic
2016–2028
AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Principal investigator · Completed · Phase 2
National Cancer Institute (NCI)
2006
Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Principal investigator · Completed · Phase 1, Phase 2
Pharmacyclics LLC.
2005–2007
Study of Motexafin Gadolinium (MGd) in Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Principal investigator · Terminated · Phase 2
Pharmacyclics LLC.
2004